NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
About this study
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
- Condition
- Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
- Tested
- Intensive Prevention Strategy
- Sponsor
- University of Texas Southwestern Medical Center
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 2
- Study condition: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
- Primary Care Provider that sees diabetes patients in clinic
Exclusion 1
- Provider does not see patients with Diabetes
Where
3 sites, 3 recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Parkland Health & Hospital System (PHHS)
Dallas, Texas, United States
Baylor Scott and White - Health System
Dallas, Texas, United States
Contact
-
Ambarish Pandey, MD
617-869-8957 ambarish.pandey@utsouthwestern.edu
-
VINAYAK SUBRAMANIAN, MD
2114-645-9868
Potential match only. Final eligibility is determined by the study team.